Dianosic

Executive Summary

Dianosic is a French medical technology company founded in 2016, dedicated to developing transformative intranasal solutions for chronic rhinitis, chronic rhinosinusitis, and intranasal bleeding (epistaxis). By collaborating with healthcare professionals, Dianosic addresses significant unmet needs in these areas, where existing treatments often suffer from poor patient adherence and suboptimal outcomes. The company's minimally invasive, drug-delivering devices aim to improve patient compliance and clinical results, positioning Dianosic as an innovator in the ENT (ear, nose, and throat) space. With a focus on patient-centric design, Dianosic's solutions have the potential to become standard of care for millions suffering from chronic nasal conditions worldwide.

Upcoming Catalysts (preview)

• Q4 2026Clinical trial results for chronic rhinosinusitis device65% success
• Q1 2027Regulatory submission (CE Mark) for epistaxis device70% success
• 2026Partnership or distribution agreement for European market50% success